NCT07745257 Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases Status NOT_YET_RECRUITING Phase PHASE2
NCT07703228 Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT07646080 Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans Status NOT_YET_RECRUITING Phase PHASE2
NCT07636226 QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer Status NOT_YET_RECRUITING Phase PHASE2/PHASE3
NCT07632209 Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment Status NOT_YET_RECRUITING Phase PHASE2
NCT07612098 Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma Status NOT_YET_RECRUITING Phase PHASE2
NCT07540390 GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. Status NOT_YET_RECRUITING Phase PHASE3
NCT07538271 A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07538258 Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07537777 Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy Status NOT_YET_RECRUITING Phase PHASE2
NCT07470840 SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Status NOT_YET_RECRUITING Phase PHASE2
NCT07443397 Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. Status RECRUITING Phase PHASE3
NCT07388875 Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC Status NOT_YET_RECRUITING Phase PHASE2
NCT07376499 Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction Status NOT_YET_RECRUITING Phase PHASE2
NCT07330544 A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy Status RECRUITING Phase PHASE2
NCT07320963 Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07172412 Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07037680 Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT Status RECRUITING Phase PHASE2
NCT07025174 Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer Status RECRUITING Phase PHASE2
NCT07010393 Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Status NOT_YET_RECRUITING Phase PHASE4